Skip to search formSkip to main contentSkip to account menu

ALN-PCSsc

Known as: inclisiran 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Inclisiran for Highest-Risk Patients: A Suggestion of Hope
Monoclonal antibodies directed against proprotein convertase subtilisin–kexin type 9 (PCSK9) can reduce LDL cholesterol and lower… 
2019
2019
ORION: Twice-Yearly Inclisiran Cut LDL-C by Half in ASCVD Patients on Statins
AHA Scientific Sessions 2019: Semi-annual injection of the novel agent inclisiran in the ORION-10 trial decreased LDL-C by 56% in… 
Review
2017
Review
2017
PCSK9 Inhibition-Reaching Physiologic LDL-C Levels “Endo, Goldstein and Brown’s Dream is Coming True”
  • M. Ec
  • 2017
  • Corpus ID: 21742619
Physiologically, in the presence of an intracellular deficit of cholesterol, the LDLR synthesis, expression and function… 
2017
2017
Therapies That Target PCSK9 Effective at Reducing LDL Cholesterol.
  • A. Slomski
  • Journal of the American Medical Association (JAMA…
  • 2017
  • Corpus ID: 37165162
In a trial published recently in the New England Journal of Medicine (NEJM), evolocumab, a monoclonal antibody that inhibits… 
2017
2017
Abstract 18934: Clinical Trial Strategies for Identifying an Evolocumab and Inclisiran Combination Regimen With Improved Safety and Efficacy Over Evolocumab Alone
Introduction: Evolocumab monoclonal antibody trials demonstrated safety and efficacy in lowering elevated LDL cholesterol (LDL-C… 
2017
2017
Inclisiran, a New Type of PCSK9 Inhibitor, Passes Phase 2
Inclisiran — a long-acting, subcutaneously delivered, synthetic, small-interfering RNA molecule directed against proprotein… 
2017
2017
Inclisiran. RNAi therapeutic targeting PCSK9, Treatment of hypercholesterolemia
2017
2017
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Ready to Target Atherosclerotic Cardiovascular Disease beyond Statins
Dyslipidemia contributes to 50% of atherogenic cardiovascular events (CVEs). Statins decrease low-density lipoprotein cholesterol… 
2017
2017
Therapies That Target PCSK 9 Effective at Reducing LDL Cholesterol Inatrialpublishedrecently inthe
  • 2017
  • Corpus ID: 207775919
at Reducing LDL Cholesterol Inatrialpublishedrecently intheNewEngland Journal of Medicine (NEJM), evolocumab, a monoclonal… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)